Genetic Deletion of the Presinilin‐Like Peptidase SPPL2B Significantly Reduces Neuroinflammation and Halts Production and Plaque Deposition in Pre‐Clinical Models of Alzheimer’s Disease
Jack Badman, Gefei Chen, Sandra Pérez Garcia, Per Nilsson, Simone Tambaro · 2025
Read Genetic Deletion of the Presinilin‐Like Peptidase SPPL2B Significantly Reduces Neuroinflammation and Halts Production and Plaque Deposition in Pre‐Clinical Models of Alzheimer’s Disease by Jack Badman, Gefei Chen, Sandra Pérez Garcia, Per Nilsson, Simone Tambaro (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11709354.txt.
Description
Jack Badman and four co-authors published a 2025 study of a brain enzyme, SPPL2B, as a drug target for Alzheimer's disease. The enzyme cuts several proteins tied to the disease, including ones driving inflammation and one, BRI2, that restrains amyloid production. The team deleted the enzyme's gene in cell cultures and in a modern Alzheimer's mouse model, then measured amyloid and inflammation markers.
Without SPPL2B, BRI2 rose and its grip on the amyloid precursor tightened. Amyloid levels fell in cell media, and young model mice showed far fewer brain plaques and much less glial inflammation in cortex and hippocampus. The authors present the enzyme as a lever on both amyloid and neuroinflammation at once. They argue blocking it deserves development as a therapy.
Catalog record
| CREATOR | Jack Badman, Gefei Chen, Sandra Pérez Garcia, Per Nilsson, Simone Tambaro |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |